For the year ending 2025-12-31, XPO had $31M increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Total adjusted ebitda | 1,272 |
| Debt extinguishment loss | -6 |
| Interest expense | 219 |
| Income tax provision | 121 |
| Depreciation and amortization expense | 521 |
| Pre-con-way acquisition environmental matter | 35 |
| Legal matters | 13 |
| Transaction and integration costs | 8 |
| Restructuring costs | 59 |
| Other | 0 |
| Income from continuing operations | 316 |
| Depreciation and amortization | 521 |
| Stock compensation expense | 77 |
| Accretion of debt | 10 |
| Deferred tax expense | 99 |
| Gains on sales of property and equipment | 17 |
| Other | -24 |
| Accounts receivable | 47 |
| Other assets | 38 |
| Accounts payable | -22 |
| Accrued expenses and other liabilities | 62 |
| Net cash provided by operating activities from continuing operations | 986 |
| Payment for purchases of property and equipment | 657 |
| Proceeds from sale of property and equipment | 41 |
| Proceeds from settlement of cross currency swaps | 0 |
| Proceeds from sale of investment | 0 |
| Net cash used in investing activities from continuing operations | -616 |
| Proceeds from issuance of debt | 0 |
| Repurchase of debt | 115 |
| Repayment of debt and finance leases | 73 |
| Payment of debt issuance costs | 3 |
| Repurchase of common stock | 125 |
| Change in bank overdrafts | 23 |
| Payment for tax withholdings for restricted shares | 50 |
| Other | 4 |
| Net cash provided by (used in) financing activities from continuing operations | -339 |
| Operating activities of discontinued operations | 0 |
| Investing activities of discontinued operations | 0 |
| Financing activities of discontinued operations | 0 |
| Net cash used in discontinued operations | 0 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | -1 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 31 |
| Cash and cash equivalents at beginning of period | 298 |
| Cash and cash equivalents at end of period | 330 |
XPO, Inc. (XPO)
XPO, Inc. (XPO)